Tempus AI, Inc. (NASDAQ:TEM) Short Interest Update

Tempus AI, Inc. (NASDAQ:TEM) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 6,140,000 shares, an increase of 20.2% from the November 30th total of 5,110,000 shares. Based on an average trading volume of 1,970,000 shares, the short-interest ratio is presently 3.1 days. Currently, 10.5% of the company’s shares are sold short.

Tempus AI Stock Down 3.6 %

Shares of TEM opened at $33.87 on Tuesday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a twelve month low of $22.89 and a twelve month high of $79.49. The company has a 50 day moving average of $49.76 and a 200-day moving average of $46.89.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TEM shares. Wolfe Research initiated coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Finally, Loop Capital boosted their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Insider Buying and Selling

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now owns 27,894 shares of the company’s stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 845,041 shares of company stock worth $35,125,473 over the last three months.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. NEA Management Company LLC boosted its position in Tempus AI by 17.8% during the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after purchasing an additional 813,169 shares during the last quarter. Novo Holdings A S acquired a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $142,605,000. Revolution Growth Management Company Inc. bought a new position in shares of Tempus AI in the second quarter valued at $128,133,000. ARK Investment Management LLC increased its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after buying an additional 1,855,459 shares during the last quarter. Finally, Alphabet Inc. acquired a new position in Tempus AI during the second quarter worth $54,289,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.